

## Chapter 4

# General Approach to Evaluating Beneficial and Adverse Effects of CAM Use in Kidney Diseases

**Mayuree Tangkiatkumjai**  
*Srinakharinwirot University, Thailand*

**Chatchai Kreepala**  
*Srinakharinwirot University, Thailand*

### **ABSTRACT**

*This chapter will address the issue of how to evaluate benefits and nephrotoxicity of complementary and alternative medicine (CAM) in chronic kidney disease, dialysis therapy, kidney transplantation, and urolithiasis. Serum creatinine, proteinuria and estimated glomerular filtration rate are standard parameters to assess kidney function. Serum creatinine is used in evaluating acute kidney injury, which is the most common nephropathy from using herbal medicine. Assessment of electrolyte imbalance and urolithiasis is included in this chapter. The modified Naranjo algorithm has been proposed as a way to evaluate renal adverse effects of herbal medicine due to a lack of disease-specific causality assessments in herbal use. Measurement of humanistic outcomes is mentioned in this chapter. The SF-36 is commonly used in evaluating quality of life in CAM users and patients with kidney diseases. The MYMOP2 is to assess individual's symptoms in CAM use and might be used in this population.*

DOI: 10.4018/978-1-5225-2882-1.ch004

## **INTRODUCTION**

Efficacy and safety of CAM on the kidneys are required to be investigated by clinical trials. This chapter will explain the principle of evaluating the benefits and adverse effects of CAM use in patients with kidney diseases, relating to conditions that include chronic kidney disease (CKD), dialysis therapy, kidney transplantation, and urolithiasis. Benefits from CAM will be measured via clinical outcomes, such as slowing the progression of CKD, preventing allograft rejection, improving CKD complications, and providing kidney stone relief. The progression of CKD is measured using an estimated glomerular filtration rate (eGFR). Benefits from CAM are not only seen in clinical outcomes, but also humanistic ones. Humanistic outcomes are defined as an individual's perspective on symptom relief, health-related quality of life, and health satisfaction (Schena, 2000). These outcomes have been measured in conventional medicine since the 20<sup>th</sup> century. Current evidence reports that conventional medicine is likely to improve the quality of life in patients with CKD (Travers et al., 2013). Patient-Reported Outcomes Measures (PROMs) are the current tool to measure humanistic outcomes (Refolo et al., 2012).

This chapter will explain how to assess potential renal adverse events associated with herbal and dietary supplements (HDS), whilst nephropathy of CAM will be addressed in Chapter 7. Common nephropathy related to herbal medicine and dietary supplements are acute kidney injuries (AKI), electrolyte imbalances, and urolithiasis. AKI is an abrupt reduction in kidney function measured by a rapid decline in glomerular filtration rate occurring over a period of minutes or days that results in the dysregulation of extracellular volume, waste products and electrolytes. The clinical spectrum of AKI can be attributed to any process that interferes with the renal structure or its function such as hypovolaemia, toxic drug induced renal tubular injury, acute glomerular renal diseases, acute interstitial nephritis or obstructive nephropathy (causing urinary blockage). Measurement of nephropathy will be explained in this chapter.

AKI has a significant impact on developing CKD and end-stage kidney disease. There are different definitions of AKI based on Risk, Injury, Failure, Loss of kidney function, and End stage kidney disease (RIFLE) classification (Bellomo et al., 2004), and the Acute Kidney Injury Network (AKIN) classification (Lopes et al., 2013). Each classification has its own advantages and disadvantages. The AKIN classification will be explained in

38 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage: [www.igi-global.com/chapter/general-approach-to-evaluating-beneficial-and-adverse-effects-of-cam-use-in-kidney-diseases/191964](http://www.igi-global.com/chapter/general-approach-to-evaluating-beneficial-and-adverse-effects-of-cam-use-in-kidney-diseases/191964)

## Related Content

---

### A Fourier-Bessel Expansion-Based Method for Automated Detection of Atrial Fibrillation From Electrocardiogram Signals

Ashish Sharma and Shivnarayan Patidar (2019). *Pre-Screening Systems for Early Disease Prediction, Detection, and Prevention* (pp. 248-277).

[www.irma-international.org/chapter/a-fourier-bessel-expansion-based-method-for-automated-detection-of-atrial-fibrillation-from-electrocardiogram-signals/215047](http://www.irma-international.org/chapter/a-fourier-bessel-expansion-based-method-for-automated-detection-of-atrial-fibrillation-from-electrocardiogram-signals/215047)

### Health Tourism-Based Destination Marketing

Maide Gürcü and Dilaver Tengilimolu (2018). *Medical Tourism: Breakthroughs in Research and Practice* (pp. 107-131).

[www.irma-international.org/chapter/health-tourism-based-destination-marketing/191482](http://www.irma-international.org/chapter/health-tourism-based-destination-marketing/191482)

### The Clinical Laboratory and the Commitment to Quality: Update on Best Practices and Regulatory Requirements

Marilena Stamouli and Antonia Mourtzikou (2020). *Quality Assurance in the Era of Individualized Medicine* (pp. 204-239).

[www.irma-international.org/chapter/the-clinical-laboratory-and-the-commitment-to-quality/241627](http://www.irma-international.org/chapter/the-clinical-laboratory-and-the-commitment-to-quality/241627)

### Medical Management of Trigeminal Neuralgia

Niushen Zhang (2018). *Effective Techniques for Managing Trigeminal Neuralgia* (pp. 45-69).

[www.irma-international.org/chapter/medical-management-of-trigeminal-neuralgia/203474](http://www.irma-international.org/chapter/medical-management-of-trigeminal-neuralgia/203474)

### Surfactant-Based Anhydrous Nano Carrier System for Poorly Aqueous Soluble Anti-Cancer Drugs

Shekhar Verma, Nagendra Chandrawanshi and Vishal Jain (2021). *Handbook of Research on Advancements in Cancer Therapeutics* (pp. 413-432).

[www.irma-international.org/chapter/surfactant-based-anhydrous-nano-carrier-system-for-poorly-aqueous-soluble-anti-cancer-drugs/267051](http://www.irma-international.org/chapter/surfactant-based-anhydrous-nano-carrier-system-for-poorly-aqueous-soluble-anti-cancer-drugs/267051)